The weight loss drug Wegovy has been associated with increased gastrointestinal issues, which can sometimes be severe, according to an updated warning label from the U.S. Food and Drug Administration.
About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.